top of page
Home
Technology
Pipeline
Female Stress Urinary Incontinence
About Us
Open Positions
Investors & Media
Contact
More...
Use tab to navigate through the menu items.
ALL POSTS
PUBLICATIONS
AWARDS
NEWS
MEDIA
RESOURCES
Search
Log in / Sign up
MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025
UVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the last patient in its phase 2 clinical study.
Muvon
2 hours ago
2 min read
Personalized approach to muscle regeneration holds promise for longevity - Interview with Longevity.Technology
Longevity.Technology  recently published an interview with MUVON CEO, Deana Mohr, focusing on our mission to redefine health and...
Muvon
Feb 17
1 min read
MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference
MUVON clears phase 2 interim milestone and announces participation in 2025 J.P. Morgan Healthcare Conference
Muvon
Jan 9
2 min read
INVEST IN OUR
INNOVATION
MORE INFORMATION
Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.
bottom of page
